First Release | Off-the-Shelf PBMCs Compliant with GMP and Eligible for Dual FDA–CFDA Submission Enable Compliance-Oriented iPSC Reprogramming Starting from “Zero”
Release Date:
2026-04-01 17:36
Compliance Starts from Zero: GMP-Compliant, Dual U.S.–China Regulatory Submission–Ready PBMC Stock
Induced pluripotent stem cells ( iPSC ) Technology is profoundly reshaping the landscape of regenerative medicine. From disease modeling and drug screening to cell therapy, iPSCs have already achieved early clinical success in multiple areas, including ophthalmic diseases, cardiovascular diseases, neurodegenerative disorders, and cancer immunotherapy. As of 2025, dozens of iPSC-based clinical studies have been published worldwide, with more than a hundred patients having received treatment; in February 2026, two iPSC-derived cell therapy products were approved for market launch—this medical revolution has now accelerated from the laboratory into commercialization.
However, for every iPSC-based drug developer, each step in the R&D pipeline is subject to real-world constraints: how can time, cost, and regulatory compliance be balanced? The starting point often determines the ultimate outcome. In iPSC drug development, the choice of cell source directly impacts the efficiency and safety of reprogramming.
Peripheral blood mononuclear cells (PBMCs), owing to their minimally invasive collection, genomic stability, and broad donor compatibility, have now supplanted skin fibroblasts as the widely recognized “gold-standard source material.” On this basis, rapidly identifying high-quality PBMCs that meet the criteria for dual submission to both China and the United States has become a critical component in accelerating drug development.
Compared with invasive skin biopsies or highly heterogeneous mesenchymal cells, PBMCs can be readily obtained from as little as 10 mL of venous blood and are not subject to donor age restrictions, making them an ideal starting point for large-scale manufacturing and autologous/allogeneic cell therapies. However, it is important to note that not all PBMCs meet “clinical-grade” standards. Low cell viability, substantial batch-to-batch variability, and unclear donor characteristics—any deficiency at any stage can pose risks of reprogramming failure or regulatory review challenges.
In the face of the stringent regulatory environment for dual submissions in China and the United States, compliance and traceability of cell-based products have become the first hurdle for drug developers. From CDE At the FDA, regulatory requirements for starting cells are evolving from “available” to “traceable, verifiable, and controllable.”
It is precisely against this backdrop that, He Yousheng Biology United Boteng Biotech has pioneered the launch of PBMCs that comply with both GMP standards and the dual China–U.S. regulatory submission requirements, thereby establishing a robust compliance foundation for iPSC reprogramming right at the source. The notion of “starting from ‘zero’” not only signifies the proactive avoidance of compliance risks from the very outset of R&D, but also reflects the establishment by both parties of a comprehensive, end-to-end compliance closed-loop that spans the entire process—from donor screening and sample collection to isolation, preparation, and quality control.
Empowering with a comprehensive, end-to-end PBMC workflow system compliant with both Chinese and U.S. regulatory requirements.
1. Compliance and Ethical Review
Prepare ethics review documents in both Chinese and English to meet the FDA’s submission requirements;
Adopt donor screening questionnaires and informed consent form templates that comply with FDA standards;
Design informed consent forms suitable for the commercial use of donor cells;
Conduct review activities under the GCP regulatory framework;
2. Donor Selection and Screening
The donor informed consent process is traceable on-site;
The donor’s nationality selection complies with the relevant laws and regulations of both China and the United States;
Infectious disease screening and testing shall be conducted in accordance with the methods and content specified in the declaration requirements.
The infectious disease screening process complies with CLIA standards;
Conduct blood type and HLA typing tests;
Clearly define the window period for infectious disease testing;
3. Sample Collection and Transportation
The sample collection process is traceable, and all equipment used has been validated.
Both the sample storage and transportation processes have been validated, ensuring end-to-end traceability.
4. Isolation and Preparation of PBMCs
Perform separation and preparation operations under GMP-compliant conditions and systems;
Both the isolation and cryopreservation processes have been validated.
5. PBMC Quality Control
Conduct sterility, mycoplasma, and endotoxin testing;
Perform flow cytometric phenotypic analysis;
Complete cell count and viability assays;
Perform whole-genome sequencing (WGS) and whole-exome sequencing (WES).
From donor screening and sample collection to isolation, preparation, and quality control release, Every stage strictly adheres to the highest standards of both Chinese and U.S. regulations. , He You Sheng Biological Joint Boteng Bio The pharmacodynamic data, safety assessments, and quality-control results generated from the prepared PBMCs can be seamlessly integrated into the regulatory submission dossier, thereby mitigating the risk of supplemental requests arising from compliance issues at the sample-source level and gaining valuable time for your global R&D strategy.
Review Differences and Comparative Analysis of PBMCs in Dual FDA–NMPA Submissions
For details on donor screening tests (FDA review standards), please click the link:
PBMC Advantages in Compliance with GMP and Dual China–U.S. Regulatory Submission
Source-level compliance and a fully traceable, compliant documentation chain
When filing dual applications in China and the United States, traceability and regulatory compliance of cell sources are the primary hurdles. Heyou Sheng Biotechnology has established a robust and stable pool of healthy donor resources from both Chinese and international populations, enabling it to provide clients with comprehensive compliance and approval services, including regulatory interpretation, policy analysis, domestic-investor designation, and approval for international collaborations.
Heyousheng Biotechnology has established a comprehensive documentation chain that complies with both Chinese and U.S. regulatory requirements. From the Donor Informed Consent Form and Ethics Review Approval Letter to the Collection/Isolation Records, Release Testing Reports, and Stability Data, Heyousheng provides end-to-end documentation support throughout the entire lifecycle of biological samples, ensuring that every sample is fully traceable and verifiable in the event of an inspection by regulatory authorities.
Save time and costs to streamline the R&D cycle.
Low-quality starting cells are the “silent killer” in process development—they can lead to inefficient reprogramming, repeated experimental failures, and the inadvertent depletion of limited R&D budgets. Rather than spending months screening donors and establishing a rigorous isolation and quality-control system, it is far more efficient to directly utilize validated, off-the-shelf resources. Heyou Bio’s PBMC products undergo stringent donor screening, meticulous isolation and preparation, comprehensive quality testing, and whole-genome sequencing to ensure compliance with CDE and FDA regulatory requirements, enabling research teams to focus on the core aspects of reprogramming process development and concentrate R&D resources on downstream differentiation and functional validation.
Dual quality inspection system; Chinese and English reports can be used directly for customs declaration.
HeYouSheng Biotechnology leverages Boteng Biotechnology’s high-quality GMP manufacturing system to ensure that every batch of PBMCs released from the facility meets consistent and uniform quality standards.
Each batch of PBMCs produced and prepared by Boteng Biotech undergoes a comprehensive suite of quality-control tests in accordance with both Chinese and U.S. regulatory requirements. These tests include, but are not limited to, sterility testing, mycoplasma testing, endotoxin testing, cell viability assessment, and flow cytometric analysis of key immune cell subsets such as CD3+, CD4+, and CD8+ cells. Our test reports are provided in both Chinese and English. Can be submitted directly as supporting documentation for the application. 。
We offer not only PBMC cells that comply with both Chinese and U.S. regulatory submission requirements, but also end-to-end, system-level capabilities that empower the entire workflow. In addition, Heyou Sheng Biotechnology is simultaneously launching a serum-free cell cryopreservation solution—designed for long-term cryopreservation of critical cell types such as iPSCs and PBMCs—and is developing specialized formulations tailored for MSCs, NK cells, γδ T cells An integrated, end-to-end amplification solution dedicated to becoming a one-stop supplier of primary cells, complementary reagents, and full-process services. From early-stage R&D to process scale-up, we provide comprehensive technical support and process optimization across the entire workflow, helping customers reduce complexity and enhance predictability.
Contact Information
For more details on PBMCs that comply with both Chinese and U.S. regulatory requirements, as well as sample-related test reports, please contact our Business Development Manager, Mr. Xie, at 15201775322.
Related News
This training program focuses on the regulatory standards governing the manufacturing of cell therapy products and the clinical research and translational applications of cutting-edge biomedical technologies, attracting participants from enterprises, research institutes, clinical institutions, and industry-chain representatives across the country. Standardization is the fundamental cornerstone for ensuring that these products are safe, effective, and accessible. As a one-stop upstream cell solutions provider offering primary cell services, pharmacological efficacy services, and product services, Heyousheng looks forward to engaging in in-depth exchanges with industry experts and peers.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 3: CBNK Competitor Comparison
HeYouSheng Bio’s 3.0 High-Efficiency HiXpan® NK Serum-Free Culture Kit is manufactured in strict compliance with GMP standards, and its production system adheres to relevant guidelines, including the “818 Requirements,” making it suitable for pharmaceutical-grade manufacturing and applications. In response to extensive customer demand, we have conducted a comparative analysis of culture performance against two leading commercial competitor media.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 2: PBNK Derived from Peripheral Blood
HeYouSheng Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the PBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering PBMC seed stocks or directly and efficiently expanding fresh PBMCs, to ultimately obtaining NK cells with high purity and high viability.
HeYouSheng Biotechnology, in collaboration with Boteng Biotechnology, has pioneered the launch of PBMCs that comply with both GMP standards and the dual China–U.S. regulatory submission requirements, thereby establishing a robust compliance foundation for iPSC reprogramming right at the source. The notion of “starting from ‘zero’” not only signifies the proactive avoidance of compliance risks from the very outset of R&D, but also reflects the establishment by the two companies of a comprehensive, end-to-end compliance closed-loop that spans the entire process—from donor screening and sample collection to isolation, preparation, and quality control.
818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire process as an inviolable baseline, and centers on differentiated technological innovation as the core driver. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and innovation-oriented guidance for the future direction of the industry.
Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.